Armistice Capital LLC Takes Position in Mural Oncology plc (NASDAQ:MURA)

Armistice Capital LLC acquired a new stake in Mural Oncology plc (NASDAQ:MURA) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,688,000 shares of the company’s stock, valued at approximately $5,300,000. Armistice Capital LLC owned about 0.10% of Mural Oncology at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in MURA. BBR Partners LLC bought a new position in shares of Mural Oncology during the second quarter valued at $31,000. Rhumbline Advisers acquired a new stake in Mural Oncology in the second quarter valued at $34,000. Canada Pension Plan Investment Board bought a new position in Mural Oncology during the 2nd quarter worth $70,000. Dimensional Fund Advisors LP acquired a new position in Mural Oncology during the 2nd quarter worth about $71,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Mural Oncology in the 2nd quarter valued at about $84,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Rodman & Renshaw initiated coverage on Mural Oncology in a research report on Friday, June 28th. They set a “buy” rating and a $15.00 price objective for the company.

Mural Oncology Price Performance

Shares of NASDAQ MURA opened at $3.03 on Friday. Mural Oncology plc has a twelve month low of $2.88 and a twelve month high of $17.00. The firm has a fifty day simple moving average of $3.28 and a 200 day simple moving average of $3.60.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $0.04. As a group, research analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current fiscal year.

Insider Buying and Selling at Mural Oncology

In other news, CEO Caroline Loew sold 12,531 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $2.91, for a total transaction of $36,465.21. Following the completion of the sale, the chief executive officer now owns 240,391 shares of the company’s stock, valued at approximately $699,537.81. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.